These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 22132702)
1. Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerases. Brown JA; Pack LR; Fowler JD; Suo Z Chem Res Toxicol; 2012 Jan; 25(1):225-33. PubMed ID: 22132702 [TBL] [Abstract][Full Text] [Related]
2. Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases. Brown JA; Pack LR; Fowler JD; Suo Z Antimicrob Agents Chemother; 2011 Jan; 55(1):276-83. PubMed ID: 21078938 [TBL] [Abstract][Full Text] [Related]
3. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Menéndez-Arias L; Álvarez M; Pacheco B Curr Opin Virol; 2014 Oct; 8():1-9. PubMed ID: 24814823 [TBL] [Abstract][Full Text] [Related]
4. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Zhu Y; Curtis M; Qi X; Miller MD; Borroto-Esoda K Antivir Chem Chemother; 2009; 19(4):165-76. PubMed ID: 19374144 [TBL] [Abstract][Full Text] [Related]
5. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234 [TBL] [Abstract][Full Text] [Related]
6. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Seifer M; Patty A; Serra I; Li B; Standring DN Antiviral Res; 2009 Feb; 81(2):147-55. PubMed ID: 19028525 [TBL] [Abstract][Full Text] [Related]
7. Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers. Chen H; Lawler JL; Filman DJ; Hogle JM; Coen DM mBio; 2021 Feb; 12(1):. PubMed ID: 33563814 [TBL] [Abstract][Full Text] [Related]
8. In vitro bypass of the major malondialdehyde- and base propenal-derived DNA adduct by human Y-family DNA polymerases κ, ι, and Rev1. Maddukuri L; Eoff RL; Choi JY; Rizzo CJ; Guengerich FP; Marnett LJ Biochemistry; 2010 Sep; 49(38):8415-24. PubMed ID: 20726503 [TBL] [Abstract][Full Text] [Related]
9. Distinct notch signaling expression patterns between nucleoside and nucleotide analogues treatment for hepatitis B virus infection. Wang Z; Kawaguchi K; Honda M; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S Biochem Biophys Res Commun; 2018 Jun; 501(3):682-687. PubMed ID: 29752943 [TBL] [Abstract][Full Text] [Related]
10. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Shaw T; Locarnini SA Liver; 1995 Aug; 15(4):169-84. PubMed ID: 8544639 [TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis B: Evolution over two decades. Yuen MF; Lai CL J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525 [TBL] [Abstract][Full Text] [Related]
12. Study on steady-state kinetics of nucleotide analogues incorporation by non-gel CE. Li W; Cao M; Pei L; Ling X; Li B; Yang Z Electrophoresis; 2010 Jan; 31(3):507-11. PubMed ID: 20119962 [TBL] [Abstract][Full Text] [Related]
13. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. Fung J; Seto WK; Lai CL; Yuen MF J Gastroenterol Hepatol; 2014 Mar; 29(3):428-34. PubMed ID: 24372662 [TBL] [Abstract][Full Text] [Related]
14. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799 [TBL] [Abstract][Full Text] [Related]
15. Kinetic analysis of the bypass of a bulky DNA lesion catalyzed by human Y-family DNA polymerases. Sherrer SM; Sanman LE; Xia CX; Bolin ER; Malik CK; Efthimiopoulos G; Basu AK; Suo Z Chem Res Toxicol; 2012 Mar; 25(3):730-40. PubMed ID: 22324639 [TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Qi X; Xiong S; Yang H; Miller M; Delaney WE Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025 [TBL] [Abstract][Full Text] [Related]
17. Structural Insights into the Post-Chemistry Steps of Nucleotide Incorporation Catalyzed by a DNA Polymerase. Reed AJ; Vyas R; Raper AT; Suo Z J Am Chem Soc; 2017 Jan; 139(1):465-471. PubMed ID: 27959534 [TBL] [Abstract][Full Text] [Related]
18. Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Gaillard RK; Barnard J; Lopez V; Hodges P; Bourne E; Johnson L; Allen MI; Condreay P; Miller WH; Condreay LD Antimicrob Agents Chemother; 2002 Apr; 46(4):1005-13. PubMed ID: 11897582 [TBL] [Abstract][Full Text] [Related]
19. Structural Insights into the Processing of Nucleobase-Modified Nucleotides by DNA Polymerases. Hottin A; Marx A Acc Chem Res; 2016 Mar; 49(3):418-27. PubMed ID: 26947566 [TBL] [Abstract][Full Text] [Related]